• Molecular NameAlizapride
  • SynonymAlizaprida [inn-spanish]; Alizapridum [inn-latin]
  • Weight315.377
  • Drugbank_IDDB01425
  • ACS_NO59338-93-1
  • Show 3D model
  • LogP (experiment)1.79
  • LogP (predicted, AB/LogP v2.0)1.6
  • pkaN/A
  • LogD (pH=7, predicted)-0.76
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.62
  • LogSw (predicted, AB/LogsW2.0)10.28
  • Sw (mg/ml) (predicted, ACD/Labs)0.19
  • No.of HBond Donors2
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds6
  • TPSA83.14
  • StatusFDA approved
  • AdministrationOral, intramuscular, intravenous
  • PharmacologyA dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability84.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half life3h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A